[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625428":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":34,"centralContacts":43,"locations":49,"responsibleParty":65,"collaborators":34,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":34,"eligibilityCriteria":72,"healthyVolunteers":69,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":34,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":34,"overallStatus":51,"whyStopped":34,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"The Third Xiangya Hospital of Central South University","OTHER",[8,16,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Surgical abortion routine group","EXPERIMENTAL","No estradiol valerate tablets were taken before curettage, and hysteroscopic curettage was performed directly under B-ultrasound guidance.\n\nFor patients who choose direct laparoscopic surgery, the intraoperative position is the lithotomy position of the bladder, and the anesthesia method is intravenous general anesthesia. Normal saline is used as the dilator fluid, and the dilator pressure is maintained at 110-120 mmHg. The hysteroscope enters the uterine cavity through the cervix, clearly observing the uterine cavity condition, exposing the pregnancy tissue, determining the location, size and relationship with the uterine wall of the pregnancy tissue, then expanding the cervix to size 7.5 with an expansion rod, inserting a 7mm suction tube for low negative pressure aspiration of the uterine cavity for two weeks. Then reinsert the hysteroscope, if there is residual pregnancy tissue, use a micro forceps to remove the remaining residual tissue under direct vision.",[13,14,15],"Drug: Control group","Drug: Conventional dose of estrogen","Drug: High-dose estrogen",{"label":17,"type":10,"description":18,"interventionNames":19},"Medical abortion routine group","Patients who choose to use mifepristone combined with misoprostol for medical abortion are given mifepristone 50mg, Bid, orally for 2 consecutive days, and misoprostol 600μg vaginally or 400μg sublingually on the third day. No pregnancy products are discharged after medication, and the medication is repeated once every 3h (oral) or 6h (vaginal medication). The method of taking is to take 400μg of misoprostol sublingually, and the method of intravaginal medication is to place 400μg of misoprostol. Patients who have previously met this treatment method are included in the drug treatment group.",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Medical abortion experimental group","Patients who choose to use mifepristone combined with misoprostol for medical abortion are given mifepristone 50mg, Bid, for 2 consecutive days, and misoprostol 600μg vaginally or 400μg sublingually on the third day. No pregnancy products are discharged after medication, and the medication is repeated once every 3h (oral) or 6h (vaginal medication). The method of taking is to take misoprostol 400μg sublingually, and the method of intravaginal medication is to place misoprostol 400μg. Estradiol valerate tablets are added daily for treatment, 2mg Bid, for 3 days.",[13,14,15],{"label":25,"type":10,"description":26,"interventionNames":27},"Surgical abortion experimental group","Estradiol valerate tablets were taken orally for 3 days before curettage, with a dose of 2mg Bid, and hysteroscopic curettage was performed under B-ultrasound guidance on the 4th day.",[13,14,15],[29,35,39],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","Control group","No estrogen supplementation",[21,17,25,9],null,{"type":30,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"Conventional dose of estrogen","1 day after medical abortion, give oral estradiol valerate, 1 mg Bid, for 21 days, and add dydrogesterone 10 mg Bid for the next 7 days. Take it in a cycle starting from the 5th day of the next menstruation for a total of 2 cycles.",[21,17,25,9],{"type":30,"name":40,"description":41,"armGroupLabels":42,"otherNames":34},"High-dose estrogen","1 day after abortion, give oral estradiol valerate, 2 mg Bid, for 21 days, and add dydrogesterone 10 mg Bid for the next 7 days. Take it in a cycle starting from the 5th day of the next menstruation for a total of 2 cycles.",[21,17,25,9],[44],{"name":45,"role":46,"phone":47,"phoneExt":34,"email":48},"Dabao Xu","CONTACT","13017386201","forxudabao@126.com",[50],{"facility":5,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","Changsha","Hunan","410013","China","CN",{"type":58,"coordinates":59},"Point",[60,61],112.97087,28.19874,{"lat":61,"lon":60},[64],{"name":45,"role":46,"phone":47,"phoneExt":34,"email":48},{"type":66,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100625428","a-real-world-study-comparing-the-efficacy-of-different-treatment-regimens-for-early-missed-abortion-100625428",false,"NCT07422506","A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion","Inclusion Criteria:\n\n* ①Age 18-40 years old; ②Early pregnancy missed abortion confirmed by imaging and laboratory tests; ③All indicators of routine examinations before treatment are within the normal range, and there are no serious systemic diseases; ④No indications for emergency curettage; ⑤Good compliance, follow-up observation as required (prospective study).\n\nExclusion Criteria:\n\n* ①Contraindications to medical abortion; ②Those who are allergic to estrogen and have contraindications to the use of estrogen; ③Those who cannot be followed up according to the follow-up plan; ④Thromboembolic diseases, known or suspected history of breast cancer, hormone-dependent tumors, etc.; ⑤Vaginal bleeding exceeds the usual menstrual volume; ⑥Those with severe heart, liver and kidney diseases; ⑦Accompanied by serious internal and surgical diseases, malignant tumors or mental illnesses, and cannot cooperate.","FEMALE","18 Years","40 Years",{"count":77,"type":78},580,"ESTIMATED","INTERVENTIONAL",[81],"NA","At present, there is no unified standard for the treatment of missed abortion in clinical practice. This study intends to collect clinical data of this type of disease to compare the efficacy of different treatments, and on this basis, presuppose the synergistic effect of different doses of estrogen in the process of drug induction, conduct statistical analysis of the efficacy, evaluate whether the treatment plan can achieve the therapeutic effect while reducing the occurrence of complications, and provide an effective basis for the subsequent clinical treatment of missed abortion.\n\nThis study is divided into two parts. The first part is a retrospective analysis to explore the differences between missed abortion surgery and drug treatment, clinical efficacy and reproductive outcomes; the second part is a prospective study to explore the effects of different doses of estrogen combined with surgery or drug abortion on the efficacy of missed abortion in early pregnancy, and explore the best clinical treatment method for missed abortion.",[84,85],"Missed Abortion","Early Pregnancy Failure","2026-02-12",{"date":88,"type":89},"2026-02-20","ACTUAL",{"date":91,"type":89},"2024-01-01",{"date":93,"type":78},"2035-01-01",{"name":5,"class":6},1]